Lunginnov is an innovative company focused on developing and commercializing solutions to study and diagnose endothelial dysfunction. They have a variety of laboratory reagents including monoclonal antibodies, ELISA kits, and recombinant proteins. Located in France, Lunginnov was founded in 2009 and is located at Campus de l’Institut Pasteur de Lille (Lille, North of France). Lunginnov’s missions are as follows:
- To develop, produce and commercialize solutions in order to detect, to study, to diagnose endothelial dysfunctions (active, inflammatory or injured endothelium).
- To develop, produce and commercialize reagents (research use only/RUO) products that have been validated by peer-reviewed publications.
- To develop R&D programs in order to offer new diagnostic and therapeutic solutions targeting the endothelium
As a young innovative company, Lunginnov devotes an important part of its budget to Research & Development (R&D) and is involved in collaborative projects with research centers worldwide. Lunginnov has developed a large expertise around Endocan / ESM-1 to study the endothelium and more precisely the vascular dysfunctions (of blood and lymph vessels) in diseases such as cancers (lung, kidney, brain, liver, etc.), sepsis, obesity, etc. by providing specific tools (monoclonal antibodies, assay kits and rapid tests) to clinicians and researchers.
产品列表：
| Lunginnov |
LIA-0901 |
Anti-Endocan Ab, clone MEP08 |
100 µg |
| Lunginnov |
LIA-0901S |
Anti-Endocan Ab, clone MEP08 |
20 µg |
| Lunginnov |
LIA-0901BB |
Anti-Endocan Ab, clone MEP08 biotinylated |
50 µg |
| Lunginnov |
LIA-0902 |
Anti-Endocan Ab, clone MEP21 |
100 µg |
| Lunginnov |
LIA-0902S |
Anti-Endocan Ab, clone MEP21 |
20 µg |
| Lunginnov |
LIA-0905 |
Anti-Endocan Ab, clone GGR222 |
100 µg |
| Lunginnov |
LIA-0905S |
Anti-Endocan Ab, clone GGR222 |
20 µg |
| Lunginnov |
LIA-0905BB |
Anti-Endocan Ab, clone GGR222 biotinylated |
50 µg |
| Lunginnov |
LIA-1001 |
Anti-Endocan Ab, clone MEP14 |
100 µg |
| Lunginnov |
LIA-1001S |
Anti-Endocan Ab, clone MEP14 |
20 µg |
| Lunginnov |
LIA-1001BB |
Anti-Endocan Ab, clone MEP14 biotinylated |
50 µg |
| Lunginnov |
LIA-1002 |
Anti-Endocan Ab, clone MEC15 |
100 µg |
| Lunginnov |
LIA-1002S |
Anti-Endocan Ab, clone MEC15 |
20 µg |
| Lunginnov |
LIA-1002BB |
Anti-Endocan Ab, clone MEC15 biotinylated |
50 µg |
| Lunginnov |
LIA-1003 |
Anti-Endocan Ab, clone MEP19 |
100 µg |
| Lunginnov |
LIA-1003S |
Anti-Endocan Ab, clone MEP19 |
20 µg |
| Lunginnov |
LIA-1101 |
Anti-Endocan Ab, clone GGR237 |
100 µg |
| Lunginnov |
LIA-1101S |
Anti-Endocan Ab, clone GGR237 |
20 µg |
| Lunginnov |
LIA-1101BB |
Anti-Endocan Ab, clone GGR237 biotinylated |
50 µg |
评论